| Basics |
Ocular Therapeutix, Inc.
Ocular Therapeutix Inc is a biopharmaceutical company. It is engaged in developing and commercializing therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology.
|
| IPO Date: |
July 25, 2014 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.29B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.28 | 3.22%
|
| Avg Daily Range (30 D): |
$0.24 | 3.20%
|
| Avg Daily Range (90 D): |
$0.27 | 3.77%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.76M |
| Avg Daily Volume (30 D): |
1.53M |
| Avg Daily Volume (90 D): |
1.33M |
| Trade Size |
| Avg Trade Size (Sh.): |
138 |
| Avg Trade Size (Sh.) (30 D): |
109 |
| Avg Trade Size (Sh.) (90 D): |
106 |
| Institutional Trades |
| Total Inst.Trades: |
1,069 |
| Avg Inst. Trade: |
$1.67M |
| Avg Inst. Trade (30 D): |
$1.53M |
| Avg Inst. Trade (90 D): |
$1.47M |
| Avg Inst. Trade Volume: |
.18M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.7M |
| Avg Closing Trade (30 D): |
$1.54M |
| Avg Closing Trade (90 D): |
$1.58M |
| Avg Closing Volume: |
187.83K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q3 2024 |
|
Basic EPS
|
|
$-.38
|
$-.22
|
|
Diluted EPS
|
|
$-.38
|
$-.22
|
|
Revenue
|
$
|
$ 10.7M
|
$ 15.43M
|
|
Gross Profit
|
$
|
$ 9.44M
|
$ 13.86M
|
|
Net Income / Loss
|
$
|
$ -64.05M
|
$ -36.49M
|
|
Operating Income / Loss
|
$
|
$ -63.92M
|
$ -46M
|
|
Cost of Revenue
|
$
|
$ 1.26M
|
$ 1.56M
|
|
Net Cash Flow
|
$
|
$ -42.42M
|
$ -32.47M
|
|
PE Ratio
|
|
|
|
|
|
|
